These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 20012482)

  • 21. Angiogenic signaling pathways and anti-angiogenic therapy for cancer.
    Liu ZL; Chen HH; Zheng LL; Sun LP; Shi L
    Signal Transduct Target Ther; 2023 May; 8(1):198. PubMed ID: 37169756
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-Angiogenic Drugs, Vascular Toxicity and Thromboembolism in Solid Cancer.
    Riondino S; Del Monte G; Fratangeli F; Guadagni F; Roselli M; Ferroni P
    Cardiovasc Hematol Agents Med Chem; 2017; 15(1):3-16. PubMed ID: 28137223
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Resistance to Anti-Angiogenic Therapy in Cancer-Alterations to Anti-VEGF Pathway.
    Itatani Y; Kawada K; Yamamoto T; Sakai Y
    Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29670046
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs.
    Fogli S; Porta C; Del Re M; Crucitta S; Gianfilippo G; Danesi R; Rini BI; Schmidinger M
    Cancer Treat Rev; 2020 Mar; 84():101966. PubMed ID: 32044644
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-angiogenic effects of the receptor tyrosine kinase inhibitor, pazopanib, on choroidal neovascularization in rats.
    Yafai Y; Yang XM; Niemeyer M; Nishiwaki A; Lange J; Wiedemann P; King AG; Yasukawa T; Eichler W
    Eur J Pharmacol; 2011 Sep; 666(1-3):12-8. PubMed ID: 21620822
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Contribution of tumor endothelial cells to drug resistance: anti-angiogenic tyrosine kinase inhibitors act as p-glycoprotein antagonists.
    Bani M; Decio A; Giavazzi R; Ghilardi C
    Angiogenesis; 2017 May; 20(2):233-241. PubMed ID: 28389777
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Novelties in the treatment for advanced renal-cell cancer].
    Maráz A
    Orv Hetil; 2011 Apr; 152(17):655-62. PubMed ID: 21464023
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity.
    Patyna S; Laird AD; Mendel DB; O'farrell AM; Liang C; Guan H; Vojkovsky T; Vasile S; Wang X; Chen J; Grazzini M; Yang CY; Haznedar JO; Sukbuntherng J; Zhong WZ; Cherrington JM; Hu-Lowe D
    Mol Cancer Ther; 2006 Jul; 5(7):1774-82. PubMed ID: 16891463
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib.
    Erdem L; Giovannetti E; Leon LG; Honeywell R; Peters GJ
    Curr Top Med Chem; 2012; 12(15):1649-59. PubMed ID: 22978339
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular basis for sunitinib efficacy and future clinical development.
    Faivre S; Demetri G; Sargent W; Raymond E
    Nat Rev Drug Discov; 2007 Sep; 6(9):734-45. PubMed ID: 17690708
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-Angiogenics: Current Situation and Future Perspectives.
    Zirlik K; Duyster J
    Oncol Res Treat; 2018; 41(4):166-171. PubMed ID: 29562226
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
    Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
    Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting angiogenesis for the treatment of prostate cancer.
    Antonarakis ES; Carducci MA
    Expert Opin Ther Targets; 2012 Apr; 16(4):365-76. PubMed ID: 22413953
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents.
    Le Tourneau C; Vidal L; Siu LL
    Drug Resist Updat; 2008 Jun; 11(3):99-109. PubMed ID: 18515176
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DCLAK11, a multi-tyrosine kinase inhibitor, exhibits potent antitumor and antiangiogenic activity in vitro.
    Guo XB; Chen XJ; Tong LJ; Peng X; Huang M; Liu HC; Liu H; Ding J
    Acta Pharmacol Sin; 2015 Oct; 36(10):1266-76. PubMed ID: 26027659
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy.
    Iacovelli R; Palazzo A; Procopio G; Santoni M; Trenta P; De Benedetto A; Mezi S; Cortesi E
    Br J Clin Pharmacol; 2014 Jun; 77(6):929-38. PubMed ID: 23981115
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sorafenib for lung cancer: is the "Battle" still open?
    Bria E; Pilotto S; Tortora G
    Expert Opin Investig Drugs; 2012 Oct; 21(10):1445-8. PubMed ID: 22799503
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quinazoline-based multi-tyrosine kinase inhibitors: synthesis, modeling, antitumor and antiangiogenic properties.
    Conconi MT; Marzaro G; Urbani L; Zanusso I; Di Liddo R; Castagliuolo I; Brun P; Tonus F; Ferrarese A; Guiotto A; Chilin A
    Eur J Med Chem; 2013 Sep; 67():373-83. PubMed ID: 23900004
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma: from the patient's bed to molecular mechanisms.
    Buczek M; Escudier B; Bartnik E; Szczylik C; Czarnecka A
    Biochim Biophys Acta; 2014 Jan; 1845(1):31-41. PubMed ID: 24135488
    [TBL] [Abstract][Full Text] [Related]  

  • 40. YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
    Amino N; Ideyama Y; Yamano M; Kuromitsu S; Tajinda K; Samizu K; Hisamichi H; Matsuhisa A; Shirasuna K; Kudoh M; Shibasaki M
    Clin Cancer Res; 2006 Mar; 12(5):1630-8. PubMed ID: 16533791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.